Health News Releases

  • Today December 12
July 01, 2024 16:35
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer’s disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mes
Left to right: Mitchell Rubin, Medisca CFO | Assemblyman Billy Jones | Stephane Nizri, Medisca Head
June 28, 2024 14:10
Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine
Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri
June 28, 2024 11:30
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capab
June 27, 2024 14:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary M
ENCell presented promising results from their First-in-Human Phase 1 clinical trial of the novel me
June 27, 2024 13:58
ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference
ENCell Co., Ltd., a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell
Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)
June 27, 2024 13:20
PQE Group Launches AI and Data Analytics Division: Innovation in the Service of Life Science
PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI bas
June 26, 2024 14:45
Kenvue Releases Inaugural Healthy Lives Mission Report
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Co
June 26, 2024 12:00
RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, F
June 25, 2024 09:43
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unres
June 25, 2024 09:26
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54085563&newsitemid=20240624910432&lan=en-US&anchor=TSE%3A4
June 23, 2024 16:00
Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri (https://www.esri.com/en-us/about/ab
June 23, 2024 13:54
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, to
June 23, 2024 12:47
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment
QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This locat
June 21, 2024 13:40
QPS Announces New Global Clinical Research Operations Leadership
QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medi
June 21, 2024 11:25
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to ac
June 20, 2024 14:15
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&newsitemid=20240618911375&lan=en-US&anchor=%28TSE%3A4502%2FNY
June 19, 2024 16:55
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation
June 19, 2024 15:15
Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary
Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and share warr
June 19, 2024 10:00
Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54053800&newsitemid=20240618137167&lan=en-US&anchor=Medidata&index=1&md5=9b4ee92db6a3a74cfb7
Carestream DRYVIEW 5700C (Photo: Business Wire)
June 18, 2024 15:35
Carestream Secures Crucial Business Partner Agreement in Peru
Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdmdperu.com%2F&esheet=54063578&newsitemid=2
June 18, 2024 09:05
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54062720&newsitemid=20240617592767&lan=en-US&anchor=TSE%3A4
June 16, 2024 10:00
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54061414&newsitemid=20240614852542&lan=en-US&anchor=TSE%3A4502%2FNYSE%
RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founde
June 13, 2024 14:15
RegenLab France Receives Prestigious EU-EIB Innovation Champion Award
RegenLab (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftrack.regenlab.com%2Fe%2F915601%2Ffr-accueil-%2Fnh859%2F499945919%2Fh%2FMJGMMXyPSguyCEA8gEgmux2pgRtnhNF3rpVyUTCRZ9Y&esheet=5
Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus
June 12, 2024 10:25
Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results
AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
June 07, 2024 11:55
Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the larges
25 per page50 per page75 per page100 per page